# Fulcrum Therapeutics, Inc.: insider transactions

FULC · Nasdaq · CIK 1680581 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fulc.md) · [Financials](/companies/fulc/financials.md) · [Filings](/companies/fulc/filings.md) · [Insiders](/companies/fulc/insiders.md)

## All transactions: 3

Non-derivative transactions reported on Forms 4, newest first. Codes P (purchase) and S (sale) are open-market trades. Reported price is as stated on the form, not a market price. Filter with ?type= `open-market`, `purchase`, `sale`.

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2019-07-22 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 93,750 | $16.00 | $1.5m | [Form 4](/filings/0000899243-19-020073.md) |
| 2019-07-22 | [Sanofi](/insiders/1121404.md) | 10% owner | Conversion (C) | 464,285 | $0.00 | $0 | [Form 4](/filings/0000899243-19-020073.md) |
| 2019-07-22 | [Glaxosmithkline plc](/insiders/1131399.md) | 10% owner | Conversion (C) | 1,785,714 | not reported | not reported | [Form 4](/filings/0001140361-19-013355.md) |

Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 27, 2026, 16:11 ET. No prices; not investment advice.